Trials / Completed
CompletedNCT00381719
Safety and Efficacy of AGN 203818 in Patients With Painful Diabetic Peripheral Neuropathy
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 330 (actual)
- Sponsor
- Allergan · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will explore the safety and effectiveness of different doses of AGN 203818 in treating pain in patients with painful diabetic peripheral neuropathy
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AGN 203818 | 3 mg Capsule twice daily for 4 weeks |
| DRUG | AGN 203818 | 20 mg Capsule twice daily for 4 weeks |
| DRUG | AGN 203818 | 60 mg Capsule twice daily for 4 weeks |
| DRUG | placebo capsule | Capsule twice daily for 4 weeks |
Timeline
- Start date
- 2006-10-01
- Primary completion
- 2007-11-01
- Completion
- 2007-11-01
- First posted
- 2006-09-28
- Last updated
- 2008-01-07
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00381719. Inclusion in this directory is not an endorsement.